Clinical effects of axitinib (Inlida) in the treatment of renal cancer and real feedback from patients

Axitinib is an oral small molecule tyrosine kinase inhibitor that mainly targets vascular endothelial growth factor receptors (VEGFR‑1, ‑2, ‑3) to prevent tumor growth and metastasis by inhibiting tumor angiogenesis. It is approved for use in patients with renal cell carcinoma (RCC) who have failed frontline treatment, especially for metastatic renal cell carcinoma (mRCC), providing a new option for multi-line treatment.

In key AXIS In phase III clinical studies, axitinib showed a better median progression-free survival (PFS) than sorafenib, which was 6.7 months versus 4.7 months. The objective response rate (ORR) was also significantly improved, showing that it can still effectively control tumor progression in patients who have failed previous treatments. At the same time, in patients with impaired renal function, the difference in efficacy was not significant, indicating that the drug can obtain clinical benefits in different patient groups.

In real-world use, patient reviews of axitinib have been mostly positive. Some patients reported reduced or stable tumor size and improved quality of life, but other users mentioned drug side effects such as high blood pressure, fatigue, diarrhea, or changes in thyroid function. This shows that axitinib can not only bring efficacy in practical applications, but also requires attention to individual tolerance and adverse reaction management.

Clinically, axitinib can be used as an effective option after frontline failure. Oral administration is convenient and suitable for long-term management. It is recommended that patients use it under the guidance of a specialist, regularly monitor blood pressure, renal function and blood routine, and adjust the dosage or deal with side effects in a timely manner. Taken together, axitinib has a stable performance in the treatment of mRCC and can provide patients with multiple lines of treatment with the opportunity to control tumors. At the same time, it has gained certain recognition from patients in the real world.

Reference materials:https://www.drugs.com/

xa0